Daily Cosmetic Research Analysis
Three studies stand out today: a multicenter phase 4 analysis shows single‑session rhenium-skin cancer therapy achieves high control with favorable cosmesis for shallow NMSC; a Science Advances paper unveils how mixed surfactants control water transport and stability in double emulsions, guiding cosmetic and drug delivery formulations; and rheological profiling of fat-derived products links viscoelastic properties to clinical use in facial rejuvenation.
Summary
Three studies stand out today: a multicenter phase 4 analysis shows single‑session rhenium-skin cancer therapy achieves high control with favorable cosmesis for shallow NMSC; a Science Advances paper unveils how mixed surfactants control water transport and stability in double emulsions, guiding cosmetic and drug delivery formulations; and rheological profiling of fat-derived products links viscoelastic properties to clinical use in facial rejuvenation.
Research Themes
- Noninvasive oncologic therapies with cosmetic advantages
- Surfactant engineering for cosmetic/drug delivery emulsions
- Mechanics-informed selection of fat-derived grafting materials
Selected Articles
1. Efficacy, Safety, and Patient Reported Outcomes of Rhenium-Skin Cancer Therapy for Non-Melanoma Skin Cancer: 1-Year Results from the EPIC-Skin Study.
In this multicenter phase 4 single-arm study of 140 patients (185 lesions), rhenium-SCT achieved a 94.1% complete response rate at 12 months with no procedure pain, mainly grade 1–2 radiation dermatitis, and favorable cosmesis (patient 8.1; clinician 7.7/10). Quality of life improved by 10.55 points, and no grade ≥3 toxicities were observed.
Impact: Demonstrates a highly effective, single-session, noninvasive alternative to surgery for shallow NMSC with excellent cosmetic outcomes and patient satisfaction.
Clinical Implications: Rhenium-SCT can be considered for stage I–II, ≤3 mm-deep NMSC when functional or cosmetic priorities favor nonsurgical therapy, offering high control and cosmesis with minimal toxicity.
Key Findings
- Complete response in 94.1% (174/185) of lesions at 12 months; partial response 3.2%.
- Mean quality-of-life improvement of 10.55 points (95% CI 3.79–17.31) on a 100-point scale.
- Radiation dermatitis occurred in 88% (mostly grade 1–2) and resolved; no grade 3–4 toxicities.
- Patient- and clinician-rated cosmesis scores were 8.1 and 7.7 out of 10; no reported pain during treatment.
Methodological Strengths
- Prospective, global multicenter phase 4 design with standardized patient-reported outcomes.
- Comprehensive safety and cosmesis assessments at 12 months.
Limitations
- Single-arm design without a randomized comparator.
- Interim 12-month analysis; longer-term durability beyond 1 year not yet reported.
- Eligibility restricted to shallow lesions (≤3 mm depth), limiting generalizability.
Future Directions: Randomized trials versus surgery or radiotherapy, longer follow-up, and head-to-head comparisons across lesion locations and skin types to refine selection criteria.
PURPOSE: Rhenium-skin cancer therapy (SCT) is an innovative, noninvasive radionuclide treatment for nonmelanoma skin cancer (NMSC), which is administered in a single outpatient treatment session. A global, multicenter, single-arm, phase 4 post-marketing clinical study was established to evaluate efficacy, safety, cosmesis, and patient-reported outcomes of OncoBeta rhenium-SCT for NMSC. This report details scheduled 12-month interim results, including toxicity, cosmesis, and patient-reported outcomes. METHODS AND MATERIALS: Eligible patients had biopsy-proven stage I or II basal cell carcinoma or squamous cell carcinoma (SCC) lesions ≤3 mm deep and ≤8 cm RESULTS: Response rates for 185 treated lesions from 140 patients were 94.1% (174/185) complete response, and 3.2% (6/185) partial response. The remaining lesions were classified as progressive or stable disease in 2.2% (4/185) and 0.5% (1/185), respectively. Quality of life improved by a mean 10.55 (95% CI, 3.79, 17.31) points (100-point scale) from baseline. No patients reported pain or discomfort during treatment. Most patients (88%, 129/147) developed radiation dermatitis as expected, which was predominantly grade 1 or 2 in severity and resolved rapidly. The most common 12-month toxicity in patients was grade 1 hypopigmentation (60.4%; 78/129), while there was no incidence of grade 3 or 4 toxicities at this time. Patient- and clinician-reported cosmesis visual assessment scale outcomes were broadly favorable at 8.1 and 7.7, respectively (10-point scale). CONCLUSIONS: This 12-month interim analysis of EPIC-Skin indicates rhenium-SCT is an effective and well-tolerated treatment for shallow basal cell carcinoma and SCC lesions, yielding favorable safety, cosmesis, and patient-satisfaction outcomes. These outcomes underscore the utility of rhenium-SCT as a single-session, noninvasive treatment for NMSC, offering a safe, effective, and efficient alternative to surgery for patients with functional or cosmetic considerations, and/or comorbidities.
2. Mixed surfactants for stabilizing and controlling water transport in double emulsions.
Using droplet microfluidics and SANS, the authors show that combining polymeric and monomeric surfactants can stabilize thin-shell double emulsions while enabling tunable, interface-controlled water transport via mixed reverse micelles. Polymeric surfactants prevent oil-shell drainage; monomeric surfactants above a threshold boost water transport but shorten emulsion lifespan.
Impact: Provides mechanistic design rules for surfactant combinations to achieve stable, controllable double emulsions, directly informing cosmetic and transdermal delivery formulations.
Clinical Implications: While preclinical, these insights can translate to more stable cosmetic emulsions and tunable release systems for dermal drug delivery, potentially improving product performance and shelf life.
Key Findings
- Polymeric surfactants prevented oil shell drainage, enhancing double emulsion stability.
- Monomeric surfactants, above a critical concentration, markedly increased water transport but reduced emulsion lifespan.
- Swelling kinetics and small-angle neutron scattering showed interface-controlled water transport via mixed reverse micelle solubilization.
- Droplet microfluidics produced uniform thin oil shells, enabling precise control of interfacial composition.
Methodological Strengths
- Integration of droplet microfluidics with SANS for mechanistic interrogation of transport.
- Systematic evaluation of monomeric vs polymeric surfactant roles and concentrations.
Limitations
- No in vivo or consumer product validation; applicability inferred from physicochemical data.
- Biocompatibility and long-term storage stability with active ingredients were not assessed.
Future Directions: Translate findings into prototype cosmetic/drug delivery emulsions, assess active loading/release kinetics, skin penetration, safety, and real-world stability.
Double emulsions, comprising an aqueous droplet enclosed within an oil shell, hold great potential as versatile microcompartments for a variety of applications. However, their widespread utility is often limited by inherent instability and uncontrolled water transport. In this study, we use droplet microfluidics to prepare double emulsions with uniform thin oil shells stabilized by mixed surfactant systems. By combining monomeric and polymeric surfactants, we demonstrate that polymeric surfactants enhance stability by preventing oil shell drainage, while monomeric surfactants substantially increase water transport above a critical concentration, albeit reducing the emulsion lifespan. Swelling kinetics experiments, coupled with small-angle neutron scattering analysis, reveal that interface-controlled water transport occurs via mixed reverse micelle solubilization. This study provides valuable insights into designing double emulsions with optimized surfactant compositions, enabling enhanced stability and tunable water transport, with potential applications across food, cosmetics, and drug delivery systems.
3. Rheological Characterization of Different Fat-Derived Products.
Across four fat-derived products, AMC showed the highest pre- and post-transplant viscoelasticity (G′ and G″), while Coleman fat was consistently lowest. After transplantation, elasticity (G′) decreased and viscosity (G″) increased in all products. The authors map these profiles to clinical indications: AMC for deep support, SVF-gel for superficial correction, and HDF for midface volume restoration.
Impact: Provides quantitative, mechanistic rationale to match fat-derived products to anatomical indications, moving beyond composition-only descriptions to measurable performance metrics.
Clinical Implications: Selecting fat products based on viscoelastic properties (e.g., AMC for structural support) may improve graft performance, durability, and aesthetic outcomes in facial rejuvenation.
Key Findings
- AMC had the highest elastic (G′) and viscous (G″) moduli pre-transplant; SVF-gel and HDF were intermediate; Coleman fat was lowest.
- Post-transplant, G′ decreased and G″ increased across all products, indicating reduced elasticity and increased viscosity.
- AMC maintained the highest G′ and G″ at 3 months, suggesting superior structural support over time.
- Clinical mapping: AMC for deep support, SVF-gel for superficial correction, HDF for midface volume; Coleman fat showed lowest mechanical robustness.
Methodological Strengths
- Direct rheometric quantification of multiple viscoelastic parameters (G′, G″, tanδ, τy).
- Pre/post-transplant comparisons enabling assessment of in situ changes over time.
Limitations
- Sample size and subject characteristics are not reported; clinical outcome correlations are inferential.
- Follow-up limited to 3 months; long-term mechanical evolution and resorption are unknown.
- Translational gap: no randomized clinical comparison of aesthetic outcomes between products.
Future Directions: Prospective clinical trials linking rheological metrics to graft retention and patient-reported outcomes, with longer follow-up and standardized anatomical sites.
BACKGROUND: Fat grafting has been widely used to correct soft-tissue volume loss and facial rejuvenation. Recent innovative advances have led to different types of fat-derived products. Although the composition of cells and extracellular matrix within different fat products has been reported, their physical and rheological properties are poorly defined. OBJECTIVES: The authors of this study aim to evaluate the rheological properties of different fat-derived products and assess how these properties change after transplantation. METHODS: In this study, the authors assessed the rheological properties of 4 fat-derived products-adipose matrix complex AMCs, high-density fat (HDF), stromal vascular fraction-gel (SVF-gel), and Coleman fat-before and after transplantation. Key parameters, including elastic modulus (G'), viscous modulus (G″), tan delta (tan δ), and yield stress (τy), were measured using a rheometer. RESULTS: Before transplantation, AMC exhibited the highest G' and G″, followed by SVF-gel, HDF, and Coleman fat. After transplantation, G' decreased for all products, indicating reduced elasticity, while G″ increased, suggesting increased viscosity. AMC maintained the highest G' and G″ even after 3 months, with SVF-gel and HDF showing similar values. Coleman fat had the lowest G' and G″ at all time points. CONCLUSIONS: Fat-derived products have distinct clinical applications based on their mechanical properties. AMC is ideal for deep structural support, SVF-gel for superficial corrections, and HDF for volume restoration in midface areas with volume loss. Clinicians should select products based on mechanical properties and anatomical needs to optimize outcomes.